Paediatric Precision Medicine

Project Overview

Precision medicine is a revolution in health care made possible with the discovery of thousands of new disease genes and advancements in cancer and rare disease sequencing over the past two decades. Children benefit significantly from precision medicine, with genetic conditions contributing substantially to admissions in New South Wales (NSW) paediatric hospitals (40-50%), and approximately 15-20% of childhood cancers appearing genetically predisposed.

To lead this precision medicine revolution, Luminesce Alliance launched the Paediatric Precision Medicine Program in 2019. This program exclusively focused on early diagnosis and treatment for children, limiting long-term effects and reducing the burden on the healthcare system. The program enhanced NSW’s capacity and integrated cutting-edge technologies into personalised clinical care as detailed in our Impact Report 2022-2023.

In April 2023, Luminesce Alliance secured an additional $20 million from the NSW Government to advance precision medicine. The funding will support the Enabling Platforms Program 2023-2027, dedicated to enhancing paediatric precision medicine. Its goal is to offer cutting-edge treatments and personalized care to all children, regardless of the rarity or complexity of their conditions.



We are revolutionising paediatric healthcare and research by funding cutting-edge infrastructure, research and treatments for rare conditions, and clinical trials to deliver the best possible care for patients and their families.